Tesaro Inc. (NASDAQ:TSRO)’s share price was down 4.9% on Wednesday . The company traded as low as $90.17 and last traded at $91.00, with a volume of 584,726 shares. The stock had previously closed at $95.64.

A number of equities analysts recently weighed in on TSRO shares. FBR & Co started coverage on shares of Tesaro in a research report on Wednesday, April 13th. They set an “outperform” rating and a $65.00 price objective for the company. Zacks Investment Research raised shares of Tesaro from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Thursday, April 28th. Jefferies Group reaffirmed a “buy” rating on shares of Tesaro in a research report on Sunday, May 8th. Credit Suisse Group AG started coverage on shares of Tesaro in a research report on Friday, May 13th. They set an “outperform” rating and a $56.00 price objective for the company. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Tesaro in a research report on Thursday, May 19th. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Tesaro currently has a consensus rating of “Buy” and an average target price of $79.42.

The firm’s 50 day moving average price is $81.56 and its 200 day moving average price is $52.09. The stock’s market cap is $4.63 billion.

Tesaro (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.43. During the same period in the prior year, the firm earned ($1.51) EPS. The firm earned $36.60 million during the quarter, compared to analyst estimates of $4.98 million. Equities research analysts anticipate that Tesaro Inc. will post ($7.29) earnings per share for the current fiscal year.

In related news, VP Edward C. English sold 7,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $40.75, for a total transaction of $285,250.00. Following the completion of the transaction, the vice president now owns 3,500 shares of the company’s stock, valued at $142,625. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jeffrey H. Hanke sold 12,500 shares of the company’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $74.35, for a total transaction of $929,375.00. Following the transaction, the vice president now directly owns 12,500 shares of the company’s stock, valued at approximately $929,375. The disclosure for this sale can be found here.

A number of institutional investors recently modified their holdings of the company. Jennison Associates LLC raised its position in shares of Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock valued at $49,100,000 after buying an additional 574,041 shares during the period. Bank of Montreal Can increased its stake in Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock valued at $1,275,000 after buying an additional 24,119 shares in the last quarter. Mutual of America Capital Management LLC increased its stake in Tesaro by 95.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 39,520 shares of the biopharmaceutical company’s stock valued at $2,068,000 after buying an additional 19,320 shares in the last quarter. Rhumbline Advisers increased its stake in Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock valued at $1,172,000 after buying an additional 1,915 shares in the last quarter. Finally, Nationwide Fund Advisors increased its stake in Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 330 shares in the last quarter.

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.